Literature DB >> 1637895

G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients.

J M Robins1, D Blevins, G Ritter, M Wulfsohn.   

Abstract

AIDS Clinical Trial Group Randomized Trial 002 compared the effect of high-dose with low-dose 3-azido-3-deoxythymidine (AZT) on the survival of AIDS patients. Embedded within the trial was an essentially uncontrolled observational study of the effect of prophylaxis therapy for pneumocystis carinii pneumonia on survival. In this paper, we estimate the causal effect of prophylaxis therapy on survival by using the method of G-estimation to estimate the parameters of a structural nested failure time model (SNFTM). Our SNFTM relates a subject's observed time of death and observed prophylaxis history to the time the subject would have died if, possibly contrary to fact, prophylaxis therapy had been withheld. We find that, under our assumptions, the data are consistent with prophylaxis therapy increasing survival by 16% or decreasing survival by 18% at the alpha = 0.05 level. The analytic approach proposed in this paper will be necessary to control bias in any epidemiologic study in which there exists a time-dependent risk factor for death, such as pneumocystis carinii pneumonia history, that (A1) influences subsequent exposure to the agent under study, for example, prophylaxis therapy, and (A2) is itself influenced by past exposure to the study agent. Conditions A1 and A2 will be true whenever there exists a time-dependent risk factor that is simultaneously a confounder and an intermediate variable.

Entities:  

Mesh:

Year:  1992        PMID: 1637895     DOI: 10.1097/00001648-199207000-00007

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  76 in total

1.  Principal stratification and attribution prohibition: good ideas taken too far.

Authors:  Marshall Joffe
Journal:  Int J Biostat       Date:  2011-09-14       Impact factor: 0.968

2.  Extended instrumental variables estimation for overall effects.

Authors:  Marshall M Joffe; Dylan Small; Thomas Ten Have; Steve Brunelli; Harold I Feldman
Journal:  Int J Biostat       Date:  2008-04-07       Impact factor: 0.968

3.  Healthy worker survivor bias in the Colorado Plateau uranium miners cohort.

Authors:  Alexander P Keil; David B Richardson; Melissa A Troester
Journal:  Am J Epidemiol       Date:  2015-04-01       Impact factor: 4.897

4.  How Confident Are We about Observational Findings in Healthcare: A Benchmark Study.

Authors:  Martijn J Schuemie; M Soledad Cepeda; Marc A Suchard; Jianxiao Yang; Yuxi Tian; Alejandro Schuler; Patrick B Ryan; David Madigan; George Hripcsak
Journal:  Harv Data Sci Rev       Date:  2020-01-31

5.  Calculating control variables with age at onset data to adjust for conditions prior to exposure.

Authors:  Michael Höfler; Tanja Brückl; Tanja Brueck; Roselind Lieb; Hans-Ulrich Wittchen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-09-09       Impact factor: 4.328

6.  Causal proportional hazards models and time-constant exposure in randomized clinical trials.

Authors:  T Loeys; E Goetghebeur; A Vandebosch
Journal:  Lifetime Data Anal       Date:  2005-12       Impact factor: 1.588

7.  Insights into different results from different causal contrasts in the presence of effect-measure modification.

Authors:  Til Stürmer; Kenneth J Rothman; Robert J Glynn
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-10       Impact factor: 2.890

8.  Causal Mediation Analyses for Randomized Trials.

Authors:  Kevin G Lynch; Mark Cary; Robert Gallop; Thomas R Ten Have
Journal:  Health Serv Outcomes Res Methodol       Date:  2008

9.  Empirical efficiency maximization: improved locally efficient covariate adjustment in randomized experiments and survival analysis.

Authors:  Daniel B Rubin; Mark J van der Laan
Journal:  Int J Biostat       Date:  2008       Impact factor: 0.968

Review 10.  The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. A review of the literature.

Authors:  D R Hoover
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.